SLAMF7 and plasma cell myeloma: SLAMF7 (also known as CS1) is a surface glycoprotein highly expressed on normal and malignant plasma cells [143] and is the target of the clinically approved monoclonal antibody elotuzumab; its consistent presence on myeloma cells and limited expression on most non-hematopoietic tissues make SLAMF7 an attractive antigen for cell-based therapies.